Evidence map›Paper›PMID 28560323›Full record

ArticleScience advances2017

CTCF facilitates DNA double-strand break repair by enhancing homologous recombination repair.

Khalid Hilmi, Maïka Jangal, Maud Marques, Tiejun Zhao, Amine Saad, Chenxi Zhang, Vincent M Luo, Alasdair Syme, Carlis Rejon, Zhenbao Yu and 7 more

Open access · goldAbstract read
In one paragraph

Article in Science advances, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
3.5field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 79 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 2 institutions in 1 country.

Khalid HilmiDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.ORCID 0000-0002-5895-2165
Maïka JangalDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Maud MarquesDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.ORCID 0000-0001-6313-9403
Tiejun ZhaoDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Amine SaadDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Chenxi ZhangDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.ORCID 0000-0001-9331-3652
Vincent M LuoDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.ORCID 0000-0002-4365-4069
Alasdair SymeDepartment of Radiation Oncology, Medical Physics Unit, Jewish General Hospital, McGill University, Montréal, Quebec H3T 1E2, Canada.ORCID 0000-0003-3173-0949
Carlis RejonDepartment of Oncology, Rosalind and Morris Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, Montréal, Quebec H3A 1A3, Canada.
Zhenbao YuDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Asiev KrumDepartment of Radiation Oncology, Medical Physics Unit, Jewish General Hospital, McGill University, Montréal, Quebec H3T 1E2, Canada.ORCID 0000-0001-9641-5152
Marc R FabianDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Stéphane RichardDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Moulay Alaoui-JamaliDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Alexander OrthweinDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Luke McCaffreyDepartment of Oncology, Rosalind and Morris Goodman Cancer Research Centre, McGill University, 1160 Pine Avenue West, Montréal, Quebec H3A 1A3, Canada.
Michael WitcherDepartments of Oncology and Experimental Medicine, Lady Davis Institute and Segal Cancer Centre, Jewish General Hospital, McGill University, 3755 Chemin Côte-Ste-Catherine, Montréal, Quebec H3T 1E2, Canada.
Jewish General Hospital · CAMcGill University · CA

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The repair of DNA double-strand breaks (DSBs) is mediated via two major pathways, nonhomologous end joining (NHEJ) and homologous recombination (HR) repair. DSB repair is vital for cell survival, genome stability, and tumor suppression. In contrast to NHEJ, HR relies on extensive homology and templated DNA synthesis to restore the sequence surrounding the break site. We report a new role for the multifunctional protein CCCTC-binding factor (CTCF) in facilitating HR-mediated DSB repair. CTCF is recruited to DSB through its zinc finger domain independently of poly(ADP-ribose) polymers, known as PARylation, catalyzed by poly(ADP-ribose) polymerase 1 (PARP-1). CTCF ensures proper DSB repair kinetics in response to γ-irradiation, and the loss of CTCF compromises HR-mediated repair. Consistent with its role in HR, loss of CTCF results in hypersensitivity to DNA damage, inducing agents and inhibitors of PARP. Mechanistically, CTCF acts downstream of BRCA1 in the HR pathway and associates with BRCA2 in a PARylation-dependent manner, enhancing BRCA2 recruitment to DSB. In contrast, CTCF does not influence the recruitment of the NHEJ protein 53BP1 or LIGIV to DSB. Together, our findings establish for the first time that CTCF is an important regulator of the HR pathway.

Indexed as

Gamma RaysBRCA1 ProteinBRCA2 ProteinCCCTC-Binding FactorCell Line, TumorDNA Breaks, Double-StrandedHEK293 CellsHumansPoly (ADP-Ribose) Polymerase-1Recombinational DNA RepairTumor Suppressor p53-Binding Protein 1BRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanCCCTC-Binding FactorCTCF protein, humanPARP1 protein, humanPoly (ADP-Ribose) Polymerase-1TP53BP1 protein, humanTumor Suppressor p53-Binding Protein 1BRCA2CTCFDNA damageHomologous RecombinationPARP inhibitorspoly ADP ribosylation

Identifiers

PMID28560323
PMCPMC5443639
OpenAlexW2619984498

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.